NIT2 Knockout Raji Polyclonal Cells comprise a polyclonal population of Raji B lymphocytes engineered via CRISPR/Cas9-mediated gene disruption to introduce loss-of-function mutations in NIT2. This polyclonal knockout pool provides a heterogeneous collection of edited cells, enabling robust functional studies without clonal artifacts associated with single-cell-derived lines. The targeted disruption of NIT2 is designed to abrogate its catalytic activity, making these cells a valuable tool for investigating nitrogen metabolism and amide hydrolysis in a B-cell lymphoma context.
The Raji cell line is a human Epstein-Barr virus (EBV)-positive B lymphocyte line originally isolated from a Burkitt lymphoma patient. It retains key characteristics of malignant B cells, including rapid proliferation and expression of B-cell surface markers. As a model for Burkitt lymphoma, Raji cells are extensively employed to study lymphomagenesis, B-cell biology, and viral oncogenesis. Their EBV positivity additionally enables research into viral latency and host-pathogen interactions. The use of Raji cells as host for NIT2 knockout provides a relevant cellular context for exploring metabolic dysregulation in B-cell malignancies.
NIT2 encodes a nitrilase family enzyme that catalyzes the deamination of amides, playing a key role in nitrogen recycling and detoxification. It functions downstream of nutrient-sensing pathways including mTOR signaling, which modulates NIT2 expression in response to amino acid availability. NIT2-mediated hydrolysis releases ammonia and alpha-keto acids, linking amide metabolism to the glutamine-glutamate-ammonia axis. Through these activities, NIT2 contributes to nitrogen balance and supply of metabolic intermediates, influencing cellular biosynthetic and energy-producing processes.
In the context of Raji Burkitt lymphoma cells, disruption of NIT2 is expected to perturb nitrogen metabolism, leading to altered amino acid utilization and ammonia production. Given the dependence of rapidly proliferating cancer cells on glutamine and other nitrogen donors, loss of NIT2 function may impair recycling of nitrogenous compounds, potentially reducing availability of critical biosynthetic precursors. This knockout model thus enables dissection of nitrogen metabolic pathways in B-cell lymphoma and provides a platform to investigate how metabolic reprogramming supports malignant growth and survival.
These NIT2 knockout polyclonal cells are suitable for a wide range of functional assays, including Western blotting and RT-qPCR to confirm protein and transcript loss, cell proliferation and colony formation assays to assess metabolic fitness, and ammonia quantification or amino acid profiling to map metabolic flux alterations. They serve as a powerful model for drug target validation studies aimed at metabolic interventions in lymphoma, enabling screening of compounds that exploit vulnerabilities in nitrogen metabolism. For further details or custom experimental applications, contact Ascent Research.
